GRI Bio Announces Reverse Stock Split
Rhea-AI Summary
GRI Bio (NASDAQ: GRI) announced a 1-for-28 reverse stock split, effective 4:01 p.m. ET on January 23, 2026, with post-split trading to begin on a split-adjusted basis on The Nasdaq Capital Market on January 26, 2026 under the ticker GRI and new CUSIP 3622AW502.
The reverse split reduces outstanding shares from ~15,016,434 to ~536,301 and is intended to help the company regain compliance with Nasdaq's minimum bid price requirement. Fractional shares will be paid in cash based on the closing price on January 23, 2026. Proportional adjustments will apply to options, warrants, convertible securities, and incentive plan shares.
Positive
- Reverse split raises per-share price to pursue Nasdaq compliance
- Outstanding shares consolidated from ~15.02M to ~536.3K
Negative
- No change to total authorized shares (no share cap reduction)
- Reverse split may reduce liquidity by consolidating free float
Market Reaction
Following this news, GRI has declined 12.65%, reflecting a significant negative market reaction. Argus tracked a trough of -8.1% from its starting point during tracking. Our momentum scanner has triggered 12 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $0.19. This price movement has removed approximately $450K from the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
While GRI was up 4.63%, several biotech peers like ADTX (+39.53%), PALI (+13.86%) and APVO (+6.16%) also rose, but there is no confirmed sector-wide momentum signal tied to this event.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 08 | Clinical data update | Positive | -4.7% | Additional positive Phase 2a IPF biomarker and FVC data for GRI-0621. |
| Dec 12 | Equity offering close | Negative | -10.0% | $8.0M public offering closing with Series F warrants at $0.75. |
| Dec 11 | Equity offering pricing | Negative | -56.5% | Pricing of $8.0M best-efforts offering with attached Series F warrants. |
| Dec 10 | Topline trial data | Positive | -12.9% | Positive Phase 2a IPF topline data meeting safety endpoint and biomarker goals. |
| Sep 11 | Interim trial update | Positive | +31.4% | Encouraging 6-week IPF data with no FVC decline and favorable biomarkers. |
The stock has often sold off on positive clinical data while reacting negatively but in line with dilutive financings, showing mixed alignment between fundamentals and price moves.
Over the last few months, GRI Bio reported multiple positive Phase 2a IPF readouts, including topline data on Dec 10, 2025 and additional flow cytometry data on Jan 8, 2026, yet shares fell after both. In December 2025, the company priced and closed an $8.0 million public offering with Series F warrants, alongside additional warrant-related prospectus activity. Earlier, a September 2025 interim IPF update with no FVC decline saw a strong positive reaction. Today’s reverse split fits into an ongoing effort to address Nasdaq listing standards after recent equity-raising steps.
Market Pulse Summary
The stock is dropping -12.7% following this news. A negative reaction despite the administrative nature of a reverse split would fit a pattern where prior structural or financing steps, such as the $8.0 million December 2025 offering, drew selling pressure. The stock already traded 98.15% below its $12.58 52-week high before this 1-for-28 split, and a similar reverse split in Feb 2025 coincided with a -17.9% move. Investors may view repeated reverse splits and equity raises as key ongoing risks.
Key Terms
reverse stock split financial
cusip financial
nasdaq capital market regulatory
AI-generated analysis. Not financial advice.
GRI’s common stock is expected to begin trading on a post-split adjusted basis on January 26, 2026
LA JOLLA, CA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the board of directors of the Company approved a 1-for-28 reverse stock split (the “Reverse Split”) of the Company’s common stock. The Reverse Split was approved by the stockholders of the Company at a special meeting of the Company held on January 15, 2026. The Reverse Split will legally take effect at 4:01 p.m. Eastern Time, on January 23, 2026. The Company’s common stock will open for trading under a new CUSIP number 3622AW 502 on The Nasdaq Capital Market on January 26, 2026, on a split-adjusted basis under the current ticker symbol “GRI.” The Reverse Split is intended to increase the per share trading price of the Company’s common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
The 1-for-28 Reverse Split will automatically convert every twenty-eight (28) current shares of the Company’s common stock into one (1) share of common stock. No fractional shares will be issued in connection with the Reverse Split. Stockholders who would otherwise hold a fractional share of the Company’s common stock following the Reverse Split will receive a cash payment in lieu thereof at a price equal to that fractional share to which the stockholder would otherwise be entitled multiplied by the closing sale price of the common stock on The Nasdaq Capital Market, as adjusted for the Reverse Split, on January 23, 2026.
The Reverse Split will reduce the number of shares of outstanding common stock from approximately 15,016,434 shares, the number of shares outstanding as of January 20, 2026, to approximately 536,301 shares. The total authorized number of shares will not be reduced. Proportional adjustments will also be made to the exercise and conversion prices of the Company’s outstanding stock options, warrants, and convertible securities, and to the number of shares issued and issuable under the Company’s stock incentive plans.
Stockholders holding their shares electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares through a bank, broker, or other nominee will have their positions automatically adjusted to reflect the Reverse Split, subject to brokers’ particular processes, and will not be required to take any action in connection with the Reverse Split. For those stockholders holding physical stock certificates, the Company’s transfer agent, Broadridge Corporate Issuers Solutions, Inc., will send instructions for exchanging those certificates for shares held electronically in book-entry form or for new certificates, in either case representing the post-split number of shares, and any payments in cash in lieu of fractional shares, if applicable.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of Natural Killer T (“NKT”) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (“iNKT”) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an RARβγ agonist shown to inhibit the activity of key immune cells, like iNKT cell activity, and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions. These forward-looking statements are based on the Company’s current beliefs and expectations. Forward-looking statements include, but are not limited to, statements regarding: the timing and effectiveness of the Reverse Split; the Company’s ability to regain or maintain compliance with the Nasdaq minimum bid price, stockholders’ equity and other listing requirements; the Company’s expectations with respect to development and commercialization of the Company’s product candidates; the timing of initiation or completion of clinical trials and availability of resulting data, the potential benefits and impact of the Company’s clinical trials and product candidates and any implication that the data or results observed in preclinical trials or earlier studies or trials will be indicative of results of later studies or clinical trials. Actual results may differ from the forward-looking statements expressed by the Company in this press release and consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, without limitation: (1) the inability to maintain the listing of the Company’s common stock on Nasdaq and to comply with applicable listing requirements; (2) changes in applicable laws or regulations; (3) the inability of the Company to raise financing in the future; (4) the success, cost and timing of the Company’s product development activities; (5) the inability of the Company to obtain and maintain regulatory clearance or approval for its respective products, and any related restrictions and limitations of any cleared or approved product; (6) the inability of the Company to identify, in-license or acquire additional technology; (7) the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently developing; (8) the size and growth potential of the markets for the Company’s products and services, and their respective ability to serve those markets, either alone or in partnership with others; (9) inaccuracy in the Company’s estimates regarding expenses, future revenue, capital requirements and needs for and the ability to obtain additional financing; (10) the Company’s ability to protect and enforce its intellectual property portfolio, including any newly issued patents; and (11) other risks and uncertainties indicated from time to time in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including the risks and uncertainties described in the “Risk Factors” section of the Company’s most recent Annual Report on Form 10-K filed with the SEC on March 14, 2025 and subsequently filed reports. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
GRI@jtcir.com
FAQ
What ratio is GRI Bio's January 2026 reverse stock split and when is it effective?
When will GRI (NASDAQ: GRI) trade on a post-split basis?
How many GRI shares will be outstanding after the reverse split?
Will GRI shareholders receive fractional post-split shares after the 1-for-28 split?
How will GRI's options, warrants and convertible securities be affected by the reverse split?
Do GRI shareholders need to take action to receive post-split shares?
